Document is current
Any future updates will be listed below
-
Authors
Leite, Giuseppe G. F.
de Brabander, Justin
Michels, Erik H. A.
Butler, Joe M.
Cremer, Olaf L.
Scicluna, Brendon P.
Sweeney, Timothy E.
Reyes, Miguel
Salomao, Reinaldo
Peters-Sengers, Hessel
van der Poll, Tom
-
Funding
Funding for this research was provided by:
Fundação de Amparo à Pesquisa do Estado de São Paulo (2022/06085-7)
European Union’s Horizon 2020 research and innovation program (847786, 847786)
European Commission (847422)
Dutch Kidney Foundation (19OK009)
Center for Translational Molecular Medicine (Grant 04I‐201)
- License Information
-
More Information
Article History
Received: 17 November 2023
Accepted: 11 March 2024
First Online: 19 March 2024
Declarations
:
: This study was part of the Molecular Diagnosis and Risk Stratification of Sepsis (MARS) project (ClinicalTrials.gov identifier NCT0195033). The MARS project was a prospective observational study in two tertiary teaching hospitals in the Netherlands. Inclusion of patients was done using an opt‑out method approved by the institutional review boards of both hospitals (IRB No. 10‑056C).
: Not applicable.
: M.R. is an employee of Genentech, a member of the Roche group, and holds equity in Roche. All other authors have no competing interests.
